AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00745199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
Study NCT05013645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterilized probiotic LfQi601
Description: Sterilized probiotic topically administered.
Study NCT05013645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel control product
Study NCT01292382 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
Study NCT01292382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
Study NCT01292382 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
Study NCT01292382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
Study NCT00151970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
Study NCT00151970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
Study NCT00151970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
Study NCT03819881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STMC-103H
Description: Live bacterial product
Study NCT03819881 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo substance
Study NCT04297813 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Advanced medicinal Therapy (MSC combined with biomaterial)
Description: Augmentation of alveolar ridge with MSC and biomaterial
Study NCT04297813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Augmentation of the alveolar ridge with bone graft
Study NCT03088475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led smartphone-based self-management programme
Description: The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource
Study NCT03088475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exiting nurse-led diabetes service
Description: the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
Study NCT01131351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: OPC-67683 film-coated tablets
Study NCT01131351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Study NCT01747967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Test
Description: Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
Study NCT00715195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plurifocal educational program
Description: intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
Study NCT01440842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Description: Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
Study NCT01440842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV insulin infusion sliding scale
Description: Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
Study NCT01931748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MELSMON
Study NCT01931748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNCNT
Study NCT03371979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Description: Administered IV
Study NCT03371979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study NCT01595984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin + mycophenolate mofetil
Description: antirejection drug, renal transplantation
Study NCT01595984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus + mycophenolate mofetil
Description: antirejection drug, renal transplantation
Study NCT04853836 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: co-ultraPEALut
Description: Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.
Study NCT04853836 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Olfactory Rehab
Description: Olfactory Rehabilitation10 minutes twice a day for all the observation period
Study NCT04853836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEA-LUT 1 sachet
Description: Only 1 sachet day of PEA-LUT no olfactory training
Study NCT04853836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEA-LUT 2 sachet day
Description: 2 sachets day of PEA-LUT no olfactory training
Study NCT03094351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagectomy
Description: Robot assisted esophagectomy with extended two field lymphadenectomy.
Study NCT03094351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophagectomy
Description: Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
Study NCT00003042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00003042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00003042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00003042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT00003042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT00003042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00003042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00003042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT03588182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Experience
Description: Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.
Study NCT03886311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
Description: Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size
Study NCT03886311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab IV Soln 100 MG/10ML
Description: NIVOLUMAB 240 mg IV over 30 min q 2 weeks
Study NCT03886311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
Description: TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
Study NCT00757536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Encircling Band
Description: ppVE and encircling band
Study NCT00757536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endolaser Photocoagulation
Description: ppVE and endolaser photocoagulation
Study NCT01347424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel , carboplatin, endostatin
Description: PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w
Study NCT01347424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin
Description: PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
Study NCT02675816 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire® Upper Airway Stimulation (UAS) System
Description: This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
Study NCT04302584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine / Vasopressin
Description: • The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
Study NCT00589498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1000 extra calories
Description: Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
Study NCT02334787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% OPA-15406 Ointment
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Study NCT02334787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406 Ointment
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
Study NCT02334787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% OPA-15406 Ointment
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Study NCT02334787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
Study NCT02334787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ointment
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
Study NCT04652154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transitioning young patients' health care trajectories
Description: New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
Study NCT04652154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitioning young patients' health care trajectories
Description: New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
Study NCT01490853 — intervention group
Intervention type: DRUG
Intervention: Interpheron alpha
Description: Long term outcom after interferon alpha discontinuation or not
Study NCT00623974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (Forteo)
Description: Subcutaneous Injection Every 12 Hours for 7 Days
Study NCT00623974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1000 milligrams by mouth (PO) Every 12 Hours
Study NCT00623974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 micrograms PO Every 12 Hours
Study NCT01301456 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous injection of placebo
Study NCT01301456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Single subcutaneous injection of PF-04856883
Study NCT01301456 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple weekly subcutaneous injections of placebo for 3 weeks
Study NCT01301456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
Study NCT04613856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration protocol - 237 mL water bolus
Description: Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
Study NCT04613856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration protocol - 500 mL water bolus
Description: Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
Study NCT00644553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
Study NCT00644553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
Study NCT02202291 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Demonstration of genetic mutations causing Raynaud's phenomenon
Description: Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family.
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
Study NCT00404066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
Study NCT00303420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase push protocol
Description: alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
Study NCT00303420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase dwell arm
Description: alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
Study NCT02879604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensatory cognitive training
Description: In addition to the usual care, method of compensatory cognitive remediation
Study NCT02879604 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual
Description: Usual care
Study NCT01087957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WalkAide
Description: Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
Study NCT01087957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ankle-Foot Orthosis (AFO)
Description: Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
Study NCT01488279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2.5 mg and Sitagliptin 100 mg
Description: Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
Study NCT01488279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone 2.5 mg and Sitagliptin 100 mg
Description: Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
Study NCT01488279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2.5 mg and placebo tablet
Description: Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
Study NCT01488279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone 2.5 mg and placebo tablet
Description: Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
Study NCT02313298 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: IMRT or similar techniques that use inverse treatment planning
Study NCT04229511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of CRKp colonization
Description: Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
Study NCT02383290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision support
Description: Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.